Curaleaf HoldingsCURLF +0.69%67 Cash Ratio is 0.36 as of Mar. 2026, which is 20% below its 10-year median of 0.45. GuruFocus rates CURLF with a GF Score™ of 67/100 and a GF Value™ of $7.98 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 975 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 62.67% on this metric.
Curaleaf Holdings has a Cash Ratio of 0.36. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Curaleaf Holdings's Cash Ratio or its related term are showing as below:
CURLF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.45 Max: 10.74
Current: 0.36
During the past 12 years, Curaleaf Holdings's highest Cash Ratio was 10.74. The lowest was 0.02. And the median was 0.45.
CURLF's Cash Ratio is ranked worse than 62.67% of 975
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs CURLF: 0.36
Curaleaf Holdings (OTCPK:CURLF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Curaleaf Holdings Cash Ratio Related Terms
Curaleaf Holdings Cash Ratio Historical Data
* Premium members only.
The historical data trend for Curaleaf Holdings's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (CURLF) has a Cash Ratio of 0.36 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Curaleaf Holdings and its competitors. This is 20% below median its historical median of 0.45. Over the past decade, Curaleaf Holdings' Cash Ratio has ranged from 0.02 to 10.74. According to the industry distribution chart, Curaleaf Holdings ranks #611 out of 975 companies in the Drug Manufacturers industry, placing it in the top 62.7%.
Is Curaleaf Holdings' Cash Ratio too high?
Curaleaf Holdings' current Cash Ratio of 0.36 is 20% below median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 10.74. The Drug Manufacturers industry median Cash Ratio is 0.61. Curaleaf Holdings' value of 0.36 is 41% below this industry median. Based on the distribution chart, Curaleaf Holdings ranks #611 out of 975 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #611 out of 975 companies for Cash Ratio. This places Curaleaf Holdings in the lower half of its industry. The industry median Cash Ratio is 0.61. Curaleaf Holdings' value of 0.36 is 41% below this benchmark. Historically, Curaleaf Holdings' own Cash Ratio has ranged from 0.02 to 10.74 over the past decade. While the company's 10-year median is 0.45 vs. the industry median of 0.61, Curaleaf Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current Cash Ratio of 0.36 is 41% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current Cash Ratio is 0.36, which is 20% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.98, compared to a current price of $9.47 — trading 18.6% above its estimated fair value. The current Cash Ratio is 0.36, which is 20% below median its 10-year median of 0.45 and 41% below the Drug Manufacturers industry median of 0.61. Curaleaf Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current Cash Ratio is 0.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.47 is trading 18.6% above its estimated GF Value™ of $7.98.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
Cash Ratio: 0.36 (20% below median its 10-year median of 0.45)
GF Value™: $7.98 vs. price of $9.47 (18.6% above fair value)
Industry Position: 41% below the Drug Manufacturers median (#611 of 975)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
67GF Score
Get the complete analysis for CURLF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
